RE:RE:RE:RE:Spectral mgnt may requst an extension for a U.S. listing I agree with you that the range for a reverse split for shareholder approval should be lowered to 1:5 assuming that the range shareholders approve is "cut in stone" and forces the company to not do a reverse split below what shareholders approve. Personally, I'm more concerned with the upper number of 1:20 and cringe when I think a reverse split would be that high.
I have to disagree with you in that I would like to see a significant announcement (milestone) before they start the application process. We are awaiting several significant announcements. Maybe it makes the most sense strategically to announce a milestone event and start the application process for a U.S. listing on the same day?
As for spinning off Dialco... I don't think that would occur before the in-home test is completed and we know the results i.e. May/June 2022.
Best case scenario ... the Phase III (B) test is halted after a mid test update and efficacy is such that Spectral is able to apply earlier than anticipated for FDA approval of PMX. (Though I'm not holding my breath on this one.)